Three Seasons Wealth LLC Acquires Shares of 12,625 Abbott Laboratories (NYSE:ABT)

Three Seasons Wealth LLC acquired a new position in shares of Abbott Laboratories (NYSE:ABT - Free Report) during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 12,625 shares of the healthcare product maker's stock, valued at approximately $1,428,000.

Several other large investors have also recently bought and sold shares of the business. Redwood Park Advisors LLC purchased a new stake in shares of Abbott Laboratories during the 4th quarter worth $25,000. Noble Wealth Management PBC purchased a new stake in shares of Abbott Laboratories during the 4th quarter worth $26,000. NewSquare Capital LLC boosted its position in shares of Abbott Laboratories by 78.4% during the 4th quarter. NewSquare Capital LLC now owns 239 shares of the healthcare product maker's stock worth $27,000 after purchasing an additional 105 shares in the last quarter. WealthTrak Capital Management LLC purchased a new stake in shares of Abbott Laboratories during the 4th quarter worth $28,000. Finally, Rialto Wealth Management LLC purchased a new stake in shares of Abbott Laboratories during the 4th quarter worth $29,000. Hedge funds and other institutional investors own 75.18% of the company's stock.

Abbott Laboratories Price Performance

ABT stock traded up $0.67 during trading on Monday, hitting $129.52. The stock had a trading volume of 3,833,894 shares, compared to its average volume of 6,064,275. Abbott Laboratories has a 1-year low of $99.71 and a 1-year high of $141.23. The company's 50 day moving average price is $130.54 and its two-hundred day moving average price is $122.51. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.14 and a current ratio of 1.60. The stock has a market cap of $224.63 billion, a price-to-earnings ratio of 16.93, a price-to-earnings-growth ratio of 2.52 and a beta of 0.80.

Abbott Laboratories (NYSE:ABT - Get Free Report) last posted its quarterly earnings data on Wednesday, April 16th. The healthcare product maker reported $1.09 EPS for the quarter, beating analysts' consensus estimates of $1.07 by $0.02. Abbott Laboratories had a net margin of 31.95% and a return on equity of 20.74%. The company had revenue of $10.36 billion during the quarter, compared to the consensus estimate of $10.38 billion. On average, sell-side analysts forecast that Abbott Laboratories will post 5.14 EPS for the current fiscal year.

Abbott Laboratories Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, May 15th. Stockholders of record on Tuesday, April 15th will be paid a dividend of $0.59 per share. This represents a $2.36 dividend on an annualized basis and a dividend yield of 1.82%. The ex-dividend date of this dividend is Tuesday, April 15th. Abbott Laboratories's dividend payout ratio is currently 30.61%.

Insider Activity

In related news, EVP Lisa D. Earnhardt sold 91,167 shares of the firm's stock in a transaction that occurred on Thursday, March 6th. The shares were sold at an average price of $133.82, for a total value of $12,199,967.94. Following the transaction, the executive vice president now owns 71,928 shares in the company, valued at approximately $9,625,404.96. This trade represents a 55.90 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, SVP Eric Shroff sold 562 shares of the firm's stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $138.17, for a total transaction of $77,651.54. Following the completion of the transaction, the senior vice president now owns 31,970 shares in the company, valued at $4,417,294.90. The trade was a 1.73 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 116,449 shares of company stock valued at $15,463,316 in the last 90 days. 0.46% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

Several equities research analysts have commented on ABT shares. Citigroup boosted their target price on shares of Abbott Laboratories from $135.00 to $160.00 and gave the stock a "buy" rating in a research report on Tuesday, March 4th. Wells Fargo & Company boosted their price objective on shares of Abbott Laboratories from $136.00 to $147.00 and gave the stock an "overweight" rating in a research report on Thursday, April 17th. Argus upgraded shares of Abbott Laboratories to a "strong-buy" rating in a research report on Tuesday, January 28th. Barclays boosted their price objective on shares of Abbott Laboratories from $158.00 to $159.00 and gave the stock an "overweight" rating in a research report on Thursday, April 17th. Finally, Piper Sandler reiterated an "overweight" rating and issued a $145.00 price objective (up from $133.00) on shares of Abbott Laboratories in a research report on Thursday, April 17th. Four equities research analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $142.59.

About Abbott Laboratories

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.